{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:20:38Z","timestamp":1760833238940,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.nmd.2021.11.013","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:43:54Z","timestamp":1638391434000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2355-6979","authenticated-orcid":false,"given":"Can Ebru","family":"Bekircan-Kurt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-1034","authenticated-orcid":false,"given":"Ezgi","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-3217","authenticated-orcid":false,"given":"Doruk","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Gokcem","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-2384","authenticated-orcid":false,"given":"\u00d6zlem","family":"Dikmetas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Ergul-Ulger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Kocabeyoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Irkec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-894X","authenticated-orcid":false,"given":"Vedat","family":"Hekimsoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevim","family":"Erdem-Ozdamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2021.11.013_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2021.11.013_bib0002","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0003","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"Ebenezer","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004016","article-title":"Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy","volume":"88","author":"Masuda","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.11.013_bib0006","first-page":"175","article-title":"[Review of clinical records and therapeutic trials to familial amyloidotic polyneuropathy\u2013study of 50 cases in Kumamoto (1967-1984)]","volume":"26","author":"Ikegawa","year":"1986","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nmd.2021.11.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy: familial generalizedamyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2021.11.013_bib0008","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.11.013_bib0009","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0010","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.11.013_bib0011","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mus.25210","article-title":"Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy","volume":"54","author":"Schmidt","year":"2016","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"10.1016\/j.nmd.2021.11.013_bib0012","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0013","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.23910","article-title":"Small fibers, large impact: quality of life in small-fiber neuropathy","volume":"49","author":"Bakkers","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2021.11.013_bib0014","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jpain.2010.02.003","article-title":"A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4","volume":"11","author":"Unal-Cevik","year":"2010","journal-title":"J Pain"},{"key":"10.1016\/j.nmd.2021.11.013_bib0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)90239-9","article-title":"Thermal testing: normative data and repeatability for various test algorithms","volume":"125","author":"Yarnitsky","year":"1994","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2021.11.013_bib0016","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1468-1331.2010.03023.x","volume":"17","author":"Lauria","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0017","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ene.12842","article-title":"A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg","volume":"23","author":"Provitera","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0018","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00003226-200105000-00008","article-title":"Morphology of corneal nerves using confocal microscopy","volume":"20","author":"Oliveira-Soto","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/j.nmd.2021.11.013_bib0019","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.4081\/rt.2015.5686","article-title":"Estimation of Daily Proteinuria in Patients with Amyloidosis by Using the Protein-To-Creatinine ratio in Random Urine Samples","volume":"7","author":"Talamo","year":"2015","journal-title":"Rare Tumors"},{"key":"10.1016\/j.nmd.2021.11.013_bib0020","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJM198312223092503","article-title":"Use of single voided urine samples to estimate quantitative proteinuria","volume":"309","author":"Ginsberg","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.11.013_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2021.11.013_bib0022","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14656566.2018.1554648","article-title":"An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"20","author":"Plante-Bordeneuve","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nmd.2021.11.013_bib0023","article-title":"Pharmacological treatment for familial amyloid polyneuropathy","volume":"4","author":"Magrinelli","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2021.11.013_bib0024","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jamaophthalmol.2016.1889","article-title":"Potential Role of In Vivo Confocal Microscopy for Imaging Corneal Nerves in Transthyretin Familial Amyloid Polyneuropathy","volume":"134","author":"Rousseau","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/ene.14563","article-title":"Corneal sub-basal whorl-like nerve plexus: a landmark for early and follow-up evaluation in transthyretin familial amyloid polyneuropathy","volume":"28","author":"Zhang","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2021.11.013_bib0026","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/jnnp-2013-305383","article-title":"Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M","volume":"85","author":"Lemos","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2021.11.013_bib0027","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.nmd.2015.05.010","article-title":"Three Turkish families with different transthyretin mutations","volume":"25","author":"Bekircan-Kurt","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2021.11.013_bib0028","doi-asserted-by":"crossref","first-page":"e01371","DOI":"10.1002\/brb3.1371","article-title":"Advances in the treatment of hereditary transthyretin amyloidosis: a review","volume":"9","author":"Gertz","year":"2019","journal-title":"Brain Behav"},{"key":"10.1016\/j.nmd.2021.11.013_bib0029","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2021.11.013_bib0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.neurol.2016.08.007","article-title":"Familial amyloid polyneuropathy: when does it stop to be asymptomatic and need a treatment?","volume":"172","author":"Adams","year":"2016","journal-title":"Rev Neurol (Paris)"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621007185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896621007185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:11:37Z","timestamp":1760775097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896621007185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0960896621007185"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2021.11.013","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutation","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2021.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}